Frederick L. Locke, MD
Relapsed/refractory mantle cell lymphoma (MCL) is an aggressive disease that could benefit from the addition of chimeric antigen receptor (CAR) T-cell therapy. The ongoing ZUMA-2 trial is investigating the use of the anti-CD19 CAR T-cell product axicabtagene ciloleucel (axi-cel; Yescarta) in patients with relapsed/refractory MCL (NCT02601313).
The primary endpoint of this study is to evaluate the safety and efficacy of axi-cel as measured by overall response rate (ORR), with secondary endpoints including duration of response, best objective response, and progression-free survival. Patients enrolled on this trial must have had prior therapy with an anthracycline- or bendamustine-containing chemotherapy, anti-CD20 monoclonal antibody therapy, and either ibrutinib (Imbruvica) or acalabrutinib (Calquence). The trial is estimated to have a primary completion date of July 2018.
... to read the full story